Philip Friedlander, MD, PhD
img_Philip Friedlander
ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
ASSISTANT PROFESSOR | Dermatology
Are you a patient?
Specialties
Internal Medicine, Cancer (Oncology)

MD, Columbia University College of Physicians & Surgeons

Internship, Internal Medicine, Columbia Presbyterian Medical Center

Residency, Internal Medicine, Columbia Presbyterian Medical Center

Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center

Certifications

American Board of Internal Medicine
Publications

Selected Publications

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. Paul Lorigan, Theresa Michelle Medina, Marta Nyakas, Annemie Rutten, Lynn G. Feun, Charles Lance Cowey, Miranda Payne, Israr Hussain, Timothy Kuzel, Steven O'Day, Amna Sheri, Philip Adam Friedlander, Satish Kumar, Vanja Sue Bergersen, Øivind Foss, Espen Basmo Ellingsen, Jens Bjørheim, Oliver Edgar Bechter. European Journal of Cancer

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. Mohammed M. Milhem, Trisha M. Wise-Draper, Sunandana Chandra, Glenn J. Hanna, Douglas E. Laux, Theresa M. Medina, George Ansstas, Adil Daud, Ciara M. Kelly, Steven J. O'Day, Cesar A. Perez, Michael K. Wong, Philip A. Friedlander, Timothy S. Kristedja, Melissa A. Burgess, C. Lance Cowey, Brent A. Hanks, Ryan M. Weight, Weston L. Daniel, Douglas E. Feltner, Scott Mix, Laurel Sindelar, Alice S. Bexon, Martin F. Bexon, Robert E. Michel, Shailender Bhatia. Journal for ImmunoTherapy of Cancer

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting. Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj. Cancer Discovery

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Friedlander during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Miscellaneous MedicoLegal
  • Sun Pharma Global FZE

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Iovance Biotherapeautics
  • elanco
  • GE Healthcare
  • Gilead Sciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.